Print

HVTN 101

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

Trial Details:

I Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN), IPPOX, EuroVacc
DNA-HIV-PT123,NYVAC-HIV-PT1,NYVAC-HIV-PT4,AIDSVAX B/E DNA  Gag, Env gp140, Pol-Nef C; Pox  Env gp140, Gag, Pol-Nef C; Protein Env B/E
DNA-HIV-PT123 DNA
NYVAC-HIV-PT1 Viral Vector - Pox
AIDSVAX B/E Protein
United Kingdom, South Africa
NCT01927835
http://www.clinicaltrials.gov/ct2/show/NCT01927835?term=hiv+and+vaccine&lup_s=08%2F11%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14